Leon Chen

Leon Chen is currently a Partner at The Column Group. Prior to this, they were a Venture Partner at OrbiMed from June 2013 to September 2019. Before OrbiMed, they were a Partner at Skyline Ventures from August 2007 to June 2013. At Skyline Ventures, they sourced, did diligence and negotiated new investments with a focus in therapeutics, life science tools and diagnostics. Leon was also a board member of Sutro Biopharma, Crescendo Biosciences and Genocea Biosciences and a Board observer at Celula and DiscoverX. From April 2007 to September 2007, they were an Entrepreneur in Residence at Venrock Associates. There, they worked on forming a new company in the field of epigenetics. Together with the team there they evaluated relevant targets in the space that could be a focus for novel drugs in oncology. Leon is also the Founder of KAI Pharmaceuticals, which they started in January 2002 and ran until April 2007. Prior to all of this, they were a PhD student at Stanford from January 1998 to December 2001.

Leon Chen has a MBA from Stanford University Graduate School of Business, a PhD in Pharmacology from Stanford University School of Medicine, and a Ph.D in Molecular Pharmacology from Stanford University. Leon also has a Bachelor of Arts in Biochemistry from University of California, Berkeley.

Some of their coworkers include Millie Ray - Partner, John Josey - Venture Partner, and Sarah Hymowitz - Venture Partner. Leon Chen reports to David V. Goeddel, Managing Partner.